News stories about Ultragenyx Pharmaceutical (NASDAQ:RARE) have been trending somewhat positive on Saturday, Accern reports. The research group identifies negative and positive media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Ultragenyx Pharmaceutical earned a media sentiment score of 0.17 on Accern’s scale. Accern also gave media coverage about the biopharmaceutical company an impact score of 46.7029582888005 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

Here are some of the news headlines that may have effected Accern Sentiment Analysis’s rankings:

A number of research firms have issued reports on RARE. BidaskClub raised Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating in a research note on Saturday, January 6th. Zacks Investment Research downgraded Ultragenyx Pharmaceutical from a “hold” rating to a “sell” rating in a research note on Wednesday, January 10th. Credit Suisse Group began coverage on Ultragenyx Pharmaceutical in a research note on Wednesday. They issued an “outperform” rating and a $67.00 price objective on the stock. Morgan Stanley reaffirmed an “equal weight” rating and issued a $71.00 price objective (up previously from $69.00) on shares of Ultragenyx Pharmaceutical in a research note on Friday, October 6th. Finally, Raymond James Financial reaffirmed a “buy” rating on shares of Ultragenyx Pharmaceutical in a research note on Friday, December 15th. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and eleven have given a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $72.06.

Ultragenyx Pharmaceutical (RARE) opened at $49.16 on Friday. Ultragenyx Pharmaceutical has a 1-year low of $43.14 and a 1-year high of $91.35. The stock has a market capitalization of $2,090.00, a price-to-earnings ratio of -7.05 and a beta of 1.83.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($1.87) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($1.87). The business had revenue of $0.20 million for the quarter, compared to analysts’ expectations of $0.02 million. During the same quarter in the previous year, the firm earned ($1.64) EPS. Ultragenyx Pharmaceutical’s revenue was up 81.8% compared to the same quarter last year. analysts forecast that Ultragenyx Pharmaceutical will post -7.31 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “Ultragenyx Pharmaceutical (RARE) Receiving Somewhat Favorable Press Coverage, Analysis Shows” was first reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece on another domain, it was copied illegally and reposted in violation of international copyright & trademark laws. The legal version of this piece can be accessed at https://www.watchlistnews.com/ultragenyx-pharmaceutical-rare-receiving-somewhat-favorable-press-coverage-analysis-shows/1815147.html.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.

Insider Buying and Selling by Quarter for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.